Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,521 questions in 132 reviews · Hepato-Biliary
current versionsNo studies 303 · 19.9%Ungraded 39 · 2.6%Very low 876 · 57.6%Low 216 · 14.2%Moderate 65 · 4.3%High 22 · 1.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pentoxifylline vs no intervention Health‐related quality of life · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Mortality at maximal · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 1.29 [0.7, 2.39] | 2 studies · 248 participants | Very low |
Anabolic steroids vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Mortality at maximal · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 1.96 [0.99, 3.89] | 2 studies · 255 participants | Very low |
Antioxidants vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Mortality at maximal · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 1.11 [0.8, 1.53] | 2 studies · 604 participants | Very low |
Colchicine vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Mortality at maximal · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 0.45 [0.26, 0.78] | 2 studies · 423 participants | Low |
Propylthiouracil vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Mortality at maximal · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 0.77 [0.58, 1.02] | 6 studies · 881 participants | Very low |
Pentoxifylline vs no intervention Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 1.18 [0.81, 1.74] | 1 study · 545 participants | Very low |
Pentoxifylline vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | OR 1.07 [0.76, 1.51] | 1 study · 545 participants | Very low |
Pentoxifylline vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Erythrocytapheresis vs phlebotomy Long‐term mortality · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Erythrocytapheresis vs phlebotomy Mortality · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Erythrocytapheresis vs phlebotomy Serious adverse events · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Erythrocytapheresis vs phlebotomy Health‐related quality of life EQ‐VAS. Scale from: 0 to 100. · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Erythrocytapheresis vs phlebotomy Health‐related quality of life beyond one year · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid (UDCA) vs no intervention Mortality at maximal · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 0.99 [0.6, 1.64] | 6 studies · 734 participants | Very low |
Colchicine vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Colchicine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Mortality at maximal · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 0.88 [0.51, 1.5] | 3 studies · 390 participants | Very low |
Ciclosporin vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
D‐Penicillamine vs no intervention Mortality at maximal · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 0.9 [0.57, 1.44] | 5 studies · 423 participants | Very low |
D‐Penicillamine vs no intervention Serious adverse events (proportion) ( · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 28.77 [1.57, 526.67] | 1 study · 52 participants | Very low |
D‐Penicillamine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid (UDCA) vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | 3 studies · 380 participants | Very low |
D‐Penicillamine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Mortality at maximal · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 1.84 [0.38, 8.91] | 2 studies · 158 participants | Very low |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 3.08 [0.12, 78.14] | 1 study · 74 participants | Very low |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Mortality at maximal · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | OR 1.17 [0.55, 2.51] | 2 studies · 290 participants | Very low |